Sol-Gel Technologies reports Q2 EPS $4.17 vs 71c last year

Reports Q2 revenue $17.261M vs $5.433M last year. Mori Arkin, Executive Chairman of Sol-Gel, stated: “Sol-Gel entered the second half of 2025 in a markedly stronger position. We have now completed enrollment in our pivotal Phase 3 trial of SGT-610 for Gorlin syndrome, keeping us firmly on track to report top-line data in the fourth quarter of 2026. If approved, SGT-610 is expected to be the first therapy designed to prevent new basal cell carcinomas in this underserved population, with peak revenue which we estimate at more than $300 million annually. Our continuous interaction with physicians and patients of Gorlin disease makes us more conscious than before of the debilitating effects of this disease and the urgent need for a therapy that will improve the quality of life for these patients.”